Clinical Trials Directory

Trials / Completed

CompletedNCT00671151

Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Molecular Mechanisms of COPD Exacerbations. Effect of Low-Dose Theophylline

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
35 (actual)
Sponsor
Hospital Universitari Son Dureta · Academic / Other
Sex
Male
Age
40 Years – 75 Years
Healthy volunteers
Accepted

Summary

Molecular mechanisms of COPD exacerbations and the modulating effect of low dose theophylline on that inflammation are elucidated in this project. NF-kappa B-dependent pathway and acetylation status of nuclear histones are to be studied.Design: controlled, prospective and randomized study with or without theophylline, a potent HDAC activator.Objectives: 1) To determine NF-kB activation, histone deacetylase (HDAC) and histone acetyl-transferase (HAT) activity in sputum macrophages and blood monocytes during an episode of exacerbation and 3 months later, once stability is achieved. To correlate these measurements with inflammatory and oxidative stress markers and with pulmonary function and clinical variables. 2) To assess the effect of theophylline on previous molecular, functional and clinical data. Method: 25 patients with COPD will be recruited during an episode of exacerbation requiring hospitalization. NF-kB activation, HDAC and HAT activity, markers of inflammation and oxidative stress will be determined with specific assays. These determinations will be repeated once the patient is stable and compared with smokers and non smoker controls with normal lung function

Conditions

Interventions

TypeNameDescription
DRUGTheophyllineTheophylline 100 mg bid for 3 months

Timeline

Start date
2005-06-01
Primary completion
2007-12-01
Completion
2007-12-01
First posted
2008-05-05
Last updated
2008-05-05

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT00671151. Inclusion in this directory is not an endorsement.